Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Renal Pelvic Carcinoma · Tislelizumab · PD-1 Inhibitor · Kidney-sparing · Nab-paclitaxel

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The Second Hospital of Tianjin Medical University, Tianjin, Outside U.S., China
Contact: Study coordinator (Hailong Hu) · Huhailong@tmu.edu.cn · +86 13662096232
Study coordinator · Huhailong@tmu.edu.cn

Study leads

Hailong Hu, PhD
Study Director
Tianjin Medical University Second Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC

Ureter Cancer · Renal Pelvic Carcinoma · Advanced Urothelial Carcinoma

Abroad (travel likely)Recruiting

Beijing, China · Beijing, China

Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs

Oligometastatic Disease · Ureter Cancer · Renal Pelvic Carcinoma

Abroad (travel likely)Recruiting

Beijing, China · Beijing, China